Pete Finan, PhD


Dr. Finan joined Epidarex Capital as a Venture Partner in 2014. He has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining Epidarex, Dr. Finan was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. In this role, Dr. Finan had strategic and operational oversight for the respiratory portfolio from target discovery through to proof-of-concept trials in the clinic. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. In this capacity, he led target discovery, validation and early drug discovery programs across a wide range of therapeutic areas including oncology, neuroscience, regenerative medicine, autoimmunity and inflammation. The approaches used to dissect signalling pathways and identify novel therapeutic targets have been extensively published in Nature and Cell. Dr. Finan led the initiation of the PI 3-kinase drug discovery program within Novartis and was awarded the Novartis Leading Scientist Award in 2007. Earlier in his career, Dr Finan worked at Cancer Research UK and the Yamanouchi Research Institute (now Astellas) and served as the Head of Biology at Karus Therapeutics.  Dr. Finan currently serves on the Board of Directors of Lunac Therapeutics Ltd., Clyde Biosciences Ltd., Enterprise Therapeutics Ltd., Mironid Ltd., and Topas Therapeutics Ltd. In addition to his role at Epidarex, Dr Finan is a Non-Executive Director at the Knowledge Transfer Network, a member of the Board of Directors and Scientific Advisory Board of the Keystone Symposia. Dr. Finan holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.